Finance

Aftermarket pop for 89bio following delayed IPO

NASH company 89bio may have been late to the market in pricing its IPO, but the biotech managed to upsize its offering while pricing at the midpoint of its proposed range. Demand persisted in Monday’s...

Biotech investors wary of Warren tax proposals

Biotech investors are concerned that Sen. Elizabeth Warren’s plans for funding Medicare for All could disincentivize the long-term investments that are the industry’s lifeblood. They are especially worried about unintended consequences of a proposal to...

Nov. 8 Financial Quick Takes: First day of trading for BrightGene, Tot; plus argenx, Agios and AiCure

BrightGene shines in STAR debut   BrightGene Bio-Medical Technology Co. Ltd. (Shanghai:688166) gained RMB17.90 (141%) to RMB30.61 in its first day of trading on Shanghai’s STAR board. The company raised RMB521.1 million ($74.1 million) in...

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...

eGenesis pushes to bring pig organ transplants to humans with $100M series B

eGenesis is aiming to be the first to transplant genetically engineered pig organs into humans with its $100 million series B round, which will allow the Cambridge, Mass.-based company to advance multiple programs in parallel....

More weakness among IPOs as Galera, Centogene limp into marketplace

Cancer company Galera became the latest biotech whose NASDAQ IPO fell short of expectations, while shares of diagnostics company Centogene dipped after pricing its offering at the low end of its proposed range. A third...

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...

A2 emerges with $57M series A, engineered T cells for solid tumors

A2 debuted Tuesday with a $57 million series A round and two T cell immunotherapy strategies for solid tumors. The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech...

Coda’s chemogenetics convinces investors to re-up in series A extension

Cellular data for Coda’s chemogenetic therapy convinced its existing investors to back a $15 million extension of the company’s series A round, which will enable the biotech to generate in vivo data and choose clinical...

Following JV, Sino backs Akeso's $150M series D

Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company. Loyal Valley Capital co-led the round, which...

American Cancer Society’s BrightEdge venture fund hoping to do well by doing good

BrightEdge Ventures, the venture fund of the American Cancer Society, is using the society’s reputation and resources to open doors to late-stage investment opportunities. While BrightEdge has persuaded companies that it brings value to board...

Nov. 1 Financial Quick Takes: Kira raises $13.8M series A; plus SinoMab, Tot, Shasqi and Sense Biodetection

Autoimmune play Kira launches with $13.8M series A  Kira Biotech raised A$20 million ($13.8 million) in a series A round led by OneVentures, IP Group and the Advance Queensland Business Development Fund. The Australian disease...

Foresite launches incubator aimed at meshing data science with healthcare

With its newly launched incubator, Foresite will provide its companies access to a holistic data set and analytical tools to explore how data can drive the development of personalized medicine across broad diseases. The incubator,...

Oyster Point, RAPT post gains after pricing IPOs at low end of range

Investors’ appetite for new biotech listings has shown signs of waning this fall, but Oyster Point and RAPT managed to price NASDAQ IPOs within expectations ahead of Thursday’s session, and each posted gains in the...

I-Mab looks to fill gap in NASDAQ listings by Chinese players

I-Mab Biopharma is hoping to become only the second innovative Chinese drug developer since Zai two years ago to go public on NASDAQ. The Shanghai-based company has proposed to raise up to $100 million in...